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esponsibility of InstAbstract In order to develop agents with superior chemopreventive and chemotherapeutic properties
against hepatocellular carcinomas, mitochondria-targeted hydroxycinnamic acids (MitoHCAs) were
synthesized by conjugation with a triphenylphosphonium cation. These synthetic compounds were
evaluated for their antioxidant activities in hepatic mitochondria, including against OH∙ and ROO∙
induced lipid peroxidation. H2O2 production was decreased signiﬁcantly by increasing glutathione
peroxidase and catalase activities. In addition, cell proliferation data from three cell lines (HepG2, L02
and WI38) indicated that the MitoHCAs were selective for cancer cells. Interestingly, the MitoHCAs both
with or without Ca2þ triggered mitochondrial dysfunction by inducing mitochondrial swelling, collapsing
the mitochondrial membrane potential and causing cytochrome c release. In particular, an inhibitor of the
mitochondrial permeability transition pore (mPTP), cyclosporin A, attenuated mitochondrial damage and
cell apoptosis, indicating that mPTP may be involved in the antiproliferative activity of MitoHCAs.
Further studies focused on structural optimization of these compounds are onging.
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Synthesis of hydroxycinnamic acid derivatives 1071. Introduction
The liver is responsible for detoxifying noxious metabolites and
requires substantial amounts of adenosine triphosphate (ATP) from
mitochondria to fulﬁll this biological process. Prolonged exposure
of the liver to detrimental xenobiotics causes oxidative
damage to mitochondria1,2. The resulting defective mitochondria
and decreased ATP synthesis may lead to the induction of
hepatocellular carcinomas3.
Hepatocellular carcinomas continue to be a major health
concern and are ranked as the ﬁfth most common cancer world-
wide. In China, high incidence rates have accounted for 55% of
the world's cases4,5. Typical treatments for hepatocellular carcino-
mas have included surgery, radiotherapy and chemotherapy, but
current cure rates are not satisfactory6. Currently, mitochondria
have been recognized as potential targets in cancer cells, as these
organelles are a reservoir for proteins that promote apoptotic death
when transported into the cytosol7. These ﬁndings underscore the
importance of discovering mitochondria-targeted drugs that would
protect healthy mitochondria from oxidative damage or selectively
induce apoptosis in hepatocellular carcinomas, while simulta-
neously affecting as few healthy cells as possible.
Hence, mitochondria-targeted drugs have been developed using
drug delivery carriers, such as the triphenylphosphonium (TPP)
cation, mitochondria-targeted peptides, nanoparticles, cell pene-
trating peptides, etc8. The TPP cation allows for mitochondrial
delivery via the electrical gradient across the mitochondrial inner
membrane and has been developed by Murphy et al.9. Further, as a
versatile therapeutic carrier, TPP-targeted drugs may exhibit
selectivity towards tumor cells because cancer cells maintain a
higher mitochondrial potential than non-malignant cells10. Addi-
tionally, because cancer mitochondria are structurally and func-
tionally different from their normal counterparts, cancer cells
display extensive metabolic reprogramming and are more suscep-
tible to mitochondrial perturbations7. Therefore, mitochondria-
targeted drugs have been synthesized based on active molecules,
such as 1,4-naphthoquinone11, resveratrol12, coenzyme Q13, etc.
In recent years natural products have generated signiﬁcant
interest as chemopreventive and chemotherapeutic agents14,15.
Hydroxycinnamic acids (HCAs) and their derivatives are com-
monly isolated from Chinese medicinal herbs16–18 and are found in
some plant-derived food products19. Epidemiological studies have
reported that coffee drinkers demonstrate a signiﬁcant reduction in
the risk for hepatocellular carcinomas when compared to non-
drinkers20. Recently, caffeic acid was reported to protect rat liver
from reperfusion injury via regulation of the Sirt3-mitochondrial
respiratory chain pathway21 and against tert-butyl hydroperoxide-
induced oxidative hepatic damage22. Additionally, high doses of
HCAs and their derivatives induced growth arrest and apoptosis in
a variety of tumor cells by triggering either mitochondrial
dysfunction or the mitochondria-dependent apoptotic pathway23–25.
Despite the undoubted protective effects or anticancer efﬁcacy,
clinical trials have failed to establish a link between treatment withScheme 1 Synthesis of MitoHCAs. Reagents and conditions: (i) Br(CH2
36 h (70%–85%).HCAs and cancer reduction, although this may be due to
insufﬁcient dosages to speciﬁc tissues26,27.
In this study, mitochondria-targeted HCA derivatives (MitoHCAs)
were synthesized (Scheme 1), where p-coumaric (p-CoA), caffeic
(CaA), ferulic (FA) and cinnamic acid (CA) were conjugated to the
TPP cation, consequently resulting in Mitop-CoA, MitoCaA,
MitoFA and MitoCA, respectively. The synthesized MitoHCAs
protected mitochondria from lipid peroxidation and decreased
mitochondrial H2O2 levels by regulating antioxidant enzymes. In
addition, they displayed high toxicity against human hepatoma
HepG2 cells, but low toxicity toward two healthy cell lines—human
hepatic L02 and diploid human ﬁbroblasts WI38 cells. Further,
MitoHCAs, both with and without Ca2þ, caused mitochondrial
permeability transition pore (mPTP) opening, thereby collapsing the
mitochondrial membrane potential (MMP) and causing cytochrome
c (cyt c) release in isolated hepatic mitochondria, all of which
initiate the apoptotic pathway28. Finally, cyclosporin A (CsA)
attenuated MitoCaA-induced apoptosis and mitochondria damage.2. Results and discussion
2.1. Synthesis
Synthesis of the MitoHCAs was performed as previously
described (Scheme 1)12,29. The MitoHCAs were obtained in good
yields (470%) and were characterized by 1H and 13C NMR
spectroscopy and HR-MS mass spectrometry (Supplementary
Figs. S1–S4). The purity was 495%, as determined by HPLC
analysis (Supplementary Fig. S5).
2.2. Inhibition of mitochondrial lipid peroxidation
As HCAs are excellent antioxidants, the synthesized MitoHCAs
could act as novel inhibitors of mitochondrial lipid peroxidation.
MitoCaA exhibited a dose-dependent suppression of lipid perox-
idation causing full inhibition at 6 μmol/L, while the parent
compound CaA had no effect on lipid peroxidation induced by
FeCl2/ascorbate, which generates OH
∙ radicals in situ30 (Fig. 1A).
The inhibition potency of the synthesized MitoHCAs was mea-
sured: Mitop-CoAoMitoFAoMitoCaA (Fig. 1B). MitoCA and
the control compounds (phosphonium salts butylTPP and CaA)
were all ineffective at 6 μmol/L. Additionally, similar results were
observed when mitochondria were treated with ROO∙ radicals and
MitoHCAs (Supplementary Fig. S3). Overall, these data suggest
that the inhibitory potency of HCAs against mitochondrial lipid
peroxidation was improved by addition of the TPP carrier.
2.3. Reduction of mitochondrial hydrogen peroxide levels and
possible mechanisms
Supplementation with MitoHCAs protected liver mitochondrial lipids
from exogenous ROS attack. In order to characterize this protection)4Br, Et3N, Me2CO, 50 1C, 4 h (55%–65%); (ii) PPh3, toluene, reﬂux,
Figure 1 Inhibition of lipid peroxidation in the energized hepatic mitochondria (1 mg protein/mL) induced by FeCl2/ascorbate supplementation.
(A) In the presence of the various concentrations of MitoCaA and CaA. (B) In the presence of MitoHCAs, CaA and butylTPP (6 μmol/L). The
values represent mean7SEM of three independent experiments. ***Po0.001 vs. the control groups.
Figure 2 Inhibition of H2O2 production in energized hepatic mitochondria (1 mg protein/mL). (A) In the presence of the various concentrations
of MitoCaA. (B) In the presence of MitoHCAs, CaA and butylTPP (10 μmol/L). The ﬂuorescence of the DCFDA probe was monitored by
excitation at 485 nm and recording the emission at 521 nm. The results were expressed as a percentage of the control. The values represent
mean7SEM of three independent experiments. ***Po0.001, **Po0.01, *Po0.05 vs. the control groups.
Jiyu Li et al.108further, the effect of MitoHCAs on endogenous H2O2 generation in
isolated hepatic mitochondria was investigated. H2O2 levels were
measured by relative 20,70-di-chlorodihydroﬂuorescein diacetate
(DCFDA) ﬂuorescence. Incubation of mitochondria with MitoCaA
signiﬁcantly decreased H2O2 levels in both a concentration- and time-
dependent manner (Fig. 2A). In order of increasing effect on
H2O2 concentration was Mitop-CoAoCaAoMitoFAoMitoCaA.
MitoCA and butylTPP did not affect the endogenous levels of H2O2
(Fig. 2B).
In order to further investigate the possible mechanisms by
which MitoHCAs decreased mitochondrial H2O2 concentration,
these compounds were assayed for their ability to directly
scavenge H2O2, decrease O
 ∙
2 production, or regulate antioxidant
enzymes, for example, superoxide dismutase (SOD), glutathione
peroxidase (GSH-Px) and catalase (CAT). No detectable changes
in DCFDA ﬂuorescence were noted after addition of MitoHCAs to
H2O2, indicating that these compounds do not act as radical
scavengers (results not shown). In addition, the MitoHCAs did not
alter O ∙2 production in mitochondria as measured by dihydroethi-
dium (DHE) probe ﬂuorescence. Although MitoCA and butylTPPdid not alter the activities of the antioxidant enzymes, MitoCaA,
MitoFA and Mitop-CoA signiﬁcantly increased both GSH-Px and
CAT activities (Fig. 3). Interestingly, both Mitop-CoA and
MitoCaA demonstrated r10% inhibition of mitochondrial SOD
after 30 min, whereas MitoFA did not, which is consistent with
previous observations that phenolic compounds do not inhibit
SOD activity31. Together, these results suggest that MitoHCAs
stimulate GSH-Px and CAT activites, thereby decreasing endo-
genous mitochondrial H2O2 levels.2.4. Antiproliferative activity
Next, the antiproliferative activities of MitoHCAs against human
hepatoma HepG2 cells and two normal cell lines, human hepatic
L02 and diploid human WI38 ﬁbroblasts, were investigated. With
the knowledge that MitoHCAs target the mitochondria and would
interfere with the MTT assay, the sulforhodamine B (SRB)
method, which estimates cell number indirectly by measuring
total protein content, was utilized instead, and this assay has
Table 1 Antiproliferative activity of MitoHCAsa.
Compd. IC50 (μmol/L)
HepG2 L02 WI38
24 h 48 h 24 h 48 h 24 h 48 h
MitoCA 11.2270.40 5.4070.32 105.4272.16 59.8275.77 126.5076.28 66.3172.16
Mitop-CoA 26.8071.53 15.3370.91 185.7576.39 80.5776.32 270.4578.05 112.5773.87
MitoFA 10.4270.37 6.4970.28 89.7373.47 50.7274.49 98.6372.18 53.5271.71
MitoCaA 9.1970.25 5.9670.21 118.6870.93 66.8373.49 123.5776.92 70.5772.15
CaA 200.8973.88 92.9771.35 402.95718.87 156.1478.83 280.8979.47 198.3977.78
ButylTPP 25.3571.02 12.8170.87 120.5879.97 71.4276.64 178.6773.73 88.5173.95
aValues represent mean7SEM from at least three independent experiments.
Table 2 Therapeutic index (TI) of MitoHCAs.
Compd. TIa
24 h 48 h
MitoCA 9.40 11.08
Mitop-CoA 6.93 5.26
MitoFA 8.61 7.82
MitoCaA 12.91 11.21
CaA 2.01 1.68
ButylTPP 4.76 5.58
aTI¼IC50 L02 normal cell/IC50 HepG2 cancer cell.
Figure 3 Impact of MitoHCAs on (A) SOD, (B) GSH-Px and (C) CAT activities. Energized hepatic mitochondria were incubated with the
MitoHCAs (10 μmol/L) at 25 1C for 15 and 30 min. The enzyme assays were performed utilizing standardized kits. The values represent
mean7SEM of three independent experiments. ***Po0.001, **Po0.01, *Po0.05 vs. the control groups.
Synthesis of hydroxycinnamic acid derivatives 109proven to be the most suitable in the preclinical screening of novel
therapeutic compounds32. In comparison to CA and butylTPP,
MitoHCAs exhibited enhanced antiproliferative activities toward
HepG2 cells (Table 1). MitoCA, MitoFA and MitoCaA were more
toxic to the cells, resulting in IC50 values 10 μmol/L at 24 h and
6 μmol/L at 48 h. Moreover, MitoHCAs selectively inhibited
proliferation in HepG2 cells in contrast to the non-cancerous L02
and WI38 cells; the IC50 values of the L02 and WI38 cells were
10-fold higher than for the HepG2 cells. The therapeutic index (TI)
of MitoHCAs is calculated as the ratio of antiproliferative
activities between normal cell and cancer cell lines (Table 2).
The results revealed that the most active compound, MitoCaA, had
the highest TI against HepG2 cells, with values of 12.91 at 24 hand 11.21 at 48 h, in comparison to compound CaA (TI¼2.01 and
1.68, respectively). This data indicates that the TPP-carrier
molecule improved the antiproliferative activities of the synthe-
sized HCAs, which is consistent with the mitochondria acting as a
key organelle in controlling apoptosis.2.5. Induction of apoptosis and variations in mitochondrial
morphology
As MitoCaA displayed the optimal antiproliferative activities
against HepG2 cells, the compound was further examined for its
impact on cell apoptosis and mitochondrial morphology. Mito-
Tracker Green FM was used to monitor mitochondrial morphol-
ogy. MitoCaA triggered mitochondrial fragmentation after a 4-h
treatment in a dose-dependent manner: treatment with 20 μmol/L
MitoCaA resulted in donut-shaped morphology and a discontin-
uous network of mitochondria (Fig. 4A), in contrast to the
ﬁlamentous or reticular mitochondria found in vehicle-treated
cells. Noticeably, under the same experimental conditions,
20 μmol/L MitoCaA did not cause mitochondrial damage to
normal L02 cells (Fig. 4A). Next, apoptotic cells were detected
by AnnexinV–FITC/PI double staining. MitoCaA triggered apop-
totic cell death in a dose-dependent manner (Fig. 4B). After
treatment with 20 μmol/L MitoCaA for 24 h, FITC-positive cells
accounted for 63.9% of the total cells, suggesting that apoptosis
was a crucial pathway in the cytotoxicity of MitoCaA. This data
Figure 4 (A) Mitochondrial morphology of L02 cells and HepG2 cells treated with MitoCaA or MitoCaAþCsA (0.4 μmol/L) for 4 h. The
mitochondrial network and morphology were visualized using MitoTracker Green FM staining and a confocal microscope. (B) Flow cytometry
analyses for the apoptotic induction of HepG2 cells after 24 h treatment with MitoCaA or MitoCaAþCsA (0.4 μmol/L). (C) Cell viability of
HepG2 cells after 24 h treatment with MitoCaA or MitoCaAþCsA. The values represent mean7SEM of three independent experiments.
Figure 5 Detection of swelling in energized hepatic mitochondria (1 mg protein/mL). (A) In the presence of the various MitoCaA concentrations.
(B) In the presence of 10 μmol/L MitoHCAs alone or 10 μmol/L MitoHCAsþCa2þ. (C) Inhibition of 20 μmol/L MitoCaA-induced mitochondrial
swelling by 1 μmol/L of CsA. CsA was added as indicated by the arrows. The assays were performed Z4 times with similar results. The values
represent mean7SEM of three independent experiments. ***Po0.001 vs. the control groups.
Jiyu Li et al.110suggests that MitoCaA induced apoptotic cell death through
mitochondrial impairment.
mPTP is known to be a critical component in drug-induced cell
death. The opening of mPTP occurs in response to mitochondrial
damage and the release of apoptotic factors, such as cyt c28. In
order to determine if mPTP induction was involved in MitoCaA-
induced apoptotic cell death, the effects of CsA, a known inhibitor
of mPTP opening due to its interaction with cyclophilin D28 on
MitoCaA-induced cell death and mitochondrial morphology, were
monitored. Interestingly, inclusion of CsA signiﬁcantly attenuatedcell death and mitochondrial damage in the MitoCaA model
(Fig. 4). In sum, these results indicated mPTP involvement in
MitoCaA-induced HepG2 cell death.
2.6. Induction of mitochondrial dysfunction
Based on the obtained results, the investigation was expanded to
examine the impact of the compounds on the whole mitochondria.
mPTP opening is often indicated by mitochondrial swelling.
Isolated hepatic mitochondria were treated with MitoCaA (0.01–
Figure 6 Collapse of mitochondrial membrane potential (ΔΨm). (A) In the presence of various MitoCaA concentrations. (B) In the presence of
MitoHCAs, CaA and butylTPP (10 μmol/L) with and without Ca2þ. (C) In the presence of MitoCaA (10 μmol/L) with CsA (1 μmol/L). CsA was
added as indicated by the arrows. The energized mitochondria suspensions (1 mg protein /mL) were incubated with 0.15 μmol/L of Rhodamine 123.
1 μmol/L CCCP, a respiratory uncoupler, was used to fully dissipate ΔΨm. The assays were performed Z 4 times with similar results. The values
represent mean 7 SEM of three independent experiments. ***Po0.001 vs. the control groups.
Synthesis of hydroxycinnamic acid derivatives 11120 μmol/L) and an obvious decrease in absorbance was noted in a
concentration-dependent manner, indicating large-amplitude swel-
ling in the mitochondrial matrix (Fig. 5A). Next, the induction
potency of various MitoHCAs was assessed, and neither MitoCA
nor CaA induced swelling. The other compounds triggered
swelling with increasing effect: butylTPPoMitop-CoAoMitoFA
EMitoCaA (Fig. 5B). Ca2þ is a key stimulator involved in inducing
the opening of the mPTP, and may trigger mPTP opening in
combination with other stimuli28. During the resting state, the
endogenous Ca2þ concentration should be 0.1 μmol/L in the
mitochondria33, but incubation with 0.1 μmol/L of Ca2þ had no
effect on cell swelling under the tested conditions (Fig. 5B).
However, treatment with MitoHCAs and Ca2þ intensiﬁed swelling,
indicating that MitoHCAs had a synergistic interaction with Ca2þ to
induce mPTP opening. Interestingly, the parent compound CaA failed
to cause swelling, regardless of Ca2þ challenge, implying that CaA
does not accumulate to high enough concentrations in the mitochon-
dria matrix to induce swelling. In addition, swelling induced by
MitoCaA was sensitive to CsA, as CsA blocked the swelling process
immediately upon addition (Fig. 5C).
As mPTP opening may disrupt MMP, the effect of MitoHCAs
on membrane potential was examined. Both 10 and 20 μmol/L
MitoCaA promoted a transient decrease in MMP (Fig. 6A), with a
decreasing affect among the synthesized compounds: MitoCAE
CaAEbutylTPPoMitop-CoAoMitoFAoMitoCaA, roughly cor-
relating with the previously noted induction of swelling (Fig. 6B).
Treatment with CsA in MitoCaA-supplemented mitochondria
delayed, but did not completely block, the dissipation of the
MMP (Fig. 6C). In the presence of CsA, MMP was maintained for
400 s, after which the MMP level fully dissipated. 0.1 μmol/L
Ca2þ was sufﬁcient to diminish MMP in the presence of
MitoHCAs, which was consistent with the synergistic induction
of mPTP opening caused by Ca2þ (Fig. 6B).
The release of cyt c is a characteristic feature of the mitochon-
drial apoptotic pathway, which is downstream of mPTP opening34.
After incubation with MitoHCAs, mitochondria released cyt c, as
visualized by immunoblotting (Fig. 7A). However, in the presence
of CsA, cyt c release was blocked (Fig. 7B). The total amount of
cyt c was determined by dithionite-reduction assay, and MitoCaA
induced the release of cyt c in a concentration-dependent manner
(Fig. 7C). Incubation with 10 μmol/L of all MitoHCAs induced cytc release (Fig. 7D). Both MitoFA and MitoCaA triggered
signiﬁcant release of 60 pmol cyt c/mg protein (about 2.5-fold
vs. control). However, CaA and butylTPP had no effects.
Synergistic release with Ca2þ was also observed (Fig. 7D). In
summary, MitoFA and MitoCaA were able to trigger mitochon-
drial dysfunction. Ca2þ, as a key molecule in cell and mitochon-
dria function, has synergistic actions with MitoHCAs in inducing
mitochondrial damage. Further, CsA strongly prevented the
mitochondrial dysfunction induced by MitoCaA.3. Conclusions
Mitochondrial therapies, particularly those involving mitochondria-
targeted antioxidants, have been considered to be effective in treating
cancer7,35. In this study, a TPP carrier was used to target HCAs to
mitochondria. The synthesized MitoHCAs improved the inherent
biological activities of the parent compounds and the order of activities
was MitoCA oMitop-CoAoMitoFAEMitoCaA, which was the
similar to the biological activity order of parent compound HCAs19.
MitoFA and MitoCaA have been identiﬁed as potent mitochondrial
antioxidants and antiproliferative molecules with minimal toxicity
toward non-cancerous cells. The protective effects of CsA suggested
that mPTP was involved in cell death and mitochondrial dysfunction.
The activity and mechanism of MitoFA and MitoCaA could guide
further development of HCAs as potential therapeutic drugs against
hepatocellular carcinomas.4. Experimental section
4.1. Materials and instruments
All reagents and PRMI 1640 media were obtained from Sigma–
Aldrich Ltd. (Beijing, China) or J&K Scientiﬁc Ltd. (Beijing,
China). Antioxidant enzyme assay kits were purchased from
Nanjing Jiancheng Bioengineering Institute (Nanjing, China).
The BCA protein assay kit was obtained from Beyotime Institute
of Biotechnology (Jiangsu, China). Polyvinylidine ﬂuoride mem-
branes and Centricon YM-3 were purchased from the Millipore
Corp. (USA). Rabbit anti-cyt c (AF0146) and rabbit anti-VDAC1
(DF6140) were obtained from Afﬁnity Biosciences (OH, USA).
Figure 7 Detection of cyt c release from energized mitochondria suspensions (2 mg protein/mL). (A) In the presence of 10 μmol/L MitoHCAs. a:
control; b: MitoCaA; c: MitoFA; d: Mitop-CoA; e: MitoCA. (B) a: control; b: 1 μmol/L MitoCaA; c: 20 μmol/L MitoCaA þ1 μmol/L CsA; d:
20 μmol/L MitoCaA. The blots shown are representative of three independent experiments demonstrating similar results. (C) In the presence of the
various concentrations of MitoCaA. (D) In the presence of MitoHCAs, CaA and butylTPP (10 μmol/L) with or without Ca2þ. The quantitative
assays were performed by the dithionite-reduction method. The values represent mean7SEM of three independent experiments. ***Po0.001 vs.
the control groups.
Jiyu Li et al.112Fetal bovine serum was purchased from Hangzhou Sijiqing
Biomaterials Co., Ltd. (Hangzhou, China).
1H NMR and 13C NMR spectra were recorded using a Varian
Mercury spectrometer operating at 400 MHz for 1H NMR and
100 MHz for 13C NMR. HR-MS spectra were obtained on an
Orbitrap Elite (Thermo Scientiﬁc) mass spectrometer. UV/Vis
spectra were recorded at 25 1C with a Perkin-Elmer Lambda 25
spectrophotometer that was equipped with temperature-controlled
cell holders (USA). Fluorescence intensity and ﬂuorescence
spectra were measured at 25 1C with an Inﬁnite M200 Pro
Multimode Reader (Switzerland) and a Shimadzu RF-5301 spec-
troﬂuorimeter (Japan), respectively.4.2. Chemistry
4.2.1. Synthesis procedures
The MitoHCAs and intermediates were synthesized according to
previously reported procedures12,29. The chemical structures were
conﬁrmed by 1H and 13C NMR, HR-MS-ESI (Supplementary
Figs. S1–S4)
(E)-4-(3-Phenyl)acrylate butyltriphenylphosphonium bromate
(MitoCA): 85% yield; 1H NMR (400 MHz, DMSO-d6): δ: 1.68 (m,
2H, CH2), 1.86 (m, 2H, CH2), 3.71 (m, 2H, CH2-P), 4.21 (m, 2H,
OCH2), 6.54 (d, 1H, J¼16Hz, H-α), 7.44–7.46 (m, 3H, H-3, H-4,
H-5), 7.58 (d, 1H, J¼16 Hz, H-β), 7.76–7.79 (m, 2H, H-2, H-6),
7.81–7.89 (m, 15H, PPh3);
13C NMR (100 MHz, DMSO-d6): δ: 18.93,
20.02, 29.15, 63.27, 118.35, 118.48, 119.33, 128.80, 130.65, 131.03,
134.02, 134.37, 135.35, 144.99, 166.56; HR-MS: Calcd. for
C31H30O2P, 465.1978; found 465.1970, error 1.7 ppm.
(E)-4-(3-(4-Hydroxyphenyl) acrylate butyltriphenylphospho-
nium bromate) (Mitop-CoA): 75% yield; 1H NMR (400 MHz,
DMSO-d6): δ: 1.66 (m, 2H, CH2), 1.82 (m, 2H, CH2), 3.65 (m,
2H, CH2-P), 4.17 (m, 2H, OCH2), 6.28 (d, 1H, J¼16 Hz, H-α),
6.80 (d, 2H, J¼8.8 Hz, H-3, H-5), 7.51 (d, 1H, J¼16 Hz, H-β),
7.53 (d, 2H, J¼8.8 Hz, H-2, H-6), 7.73–7.90 (m, 15H, PPh3),10.05 (s, 1H, OH); 13C NMR (100 MHz, DMSO-d6): δ: 19.81,
19.63, 28.87, 62.59, 114.10, 115.87, 118.13, 125.13, 130.31,
133.67, 135.02, 144.87, 159.87, 166.61; HR-MS: Calcd. for
C31H30O3P, 481.1927; found 481.1919, error 1.7 ppm.
(E)-4-(3-(4-Methoxyphenyl) acrylate butyltriphenylphospho-
nium bromate) (MitoFA): 70% yield; 1H NMR (400 MHz,
CDCl3): δ: 1.72 (m, 2H, CH2), 2.16 (m, 2H, CH2), 3.93 (s, 3H,
-OCH3), 4.01 (m, 2H, CH2-P), 4.23 (m, 2H, OCH2), 6.15 (d, 1H,
J¼15.6 Hz, H-α), 6.99–7.05 (m, 3H, H-2, H-5, H-6), 7.52 (d, 1H,
J¼15.6 Hz, H-β), 7.65–7.89 (m, 15H, PPh3); 13C NMR
(100 MHz, CDCl3): δ: 19.17, 21.84, 29.01, 56.04, 62.82,
109.77, 114.77, 115.02, 117.69, 122.82, 126.51, 130.36, 133.54,
134.94, 145.12, 147.03, 148.42, 167.20; HR-MS: Calcd. for
C32H32O4P, 511.2033; found 511.2088, error 1.0 ppm.
(E)-4-(3-(3,4-Dihydroxyphenyl) acrylate butyltriphenylpho-
sphonium bromate) (MitoCaA): 81% yield; 1H NMR (400 MHz,
DMSO-d6): δ: 1.63 (m, 2H, CH2), 1.81 (m, 2H, CH2), 3.66 (m,
2H, CH2-P), 4.14 (m, 2H, OCH2), 6.13 (d, 1H, J¼16 Hz, H-α),
6.76 (d, 1H, J¼8 Hz, H-5), 6.94 (d, 1H, J¼8 Hz, H-6), 7.03 (s,
1H, H-2), 7.37 (d, 1H, J¼15.6 Hz, H-β), 7.76–7.86 (m, 15H,
PPh3), 9.19 (s, 1H, OH), 9.66 (s, 1H, OH);
13C NMR (100 MHz,
DMSO-d6): δ: 18.55, 19.60, 28.84, 62.53, 113.84, 114.86, 115.87,
118.12, 121.53, 125.50, 130.29, 133.66, 135.00, 145.25, 145.70,
148.58, 166.54; HR-MS: Calcd. for C31H30O4P, 497.1876; found
497.1880, error 0.8 ppm.4.2.2. HPLC purity analysis
HPLC analysis was performed using a Waters 600 system
equipped with a Waters 2998 photodiode array detector, including
a 2707 automatic injector and a computer integrating apparatus.
The column was a Diamonsil C18 (150 mm 4.6 mm, 5 μm) and
the column compartment was kept constant at 25 1C. The injection
volume was 20.0 μL. Two mobile phases were used: (1) methanol:
acetate buffer (50:50, v/v, pH¼3.2), ﬂow-rate of 1 mL/min.
(2) acetonitrile:acetate buffer (50:50, v/v, pH¼4.0), ﬂow-rate of
Synthesis of hydroxycinnamic acid derivatives 1130.5 mL/min. Detection was measured at 300 nm. The results and
spectra are shown in Supplementary Fig. S2.
4.3. Biological studies
For the subsequent assays, the MitoHCAs were dissolved in
DMSO, with the ﬁnal concentrations of each reactant indicated
in parentheses. The ﬁnal DMSO concentration did not exceed
0.1% (v/v) and did not affect the results from the assays.
4.3.1. Preparation of hepatic mitochondria
Male Wister rats weighting 250720 g, obtained from the animal
center of the Medical College of Lanzhou University, were fasted
overnight before cervical dislocation. All the animals were cared
for and experiments were carried out in accordance with the
principles and guidelines of the National Institutes of Health guide
for the care and use of laboratory animals. All the protocols were
approved by the Ethics Committee of Lanzhou University.
Mitochondria were isolated by a standard differential centrifuga-
tion protocol36. The protein concentration was determined by
biuret assay, using BSA as a standard37. For subsequent assays
mitochondrial suspensions were incubated in the standard medium
(in mmol/L: sucrose 250, HEPES 10, KH2PO 1, glutamate 10,
malate 5; pH 7.4).
4.3.2. Mitochondrial lipid peroxidation assay
In order to quantify the amount of lipid peroxidation in mitochondria
suspended in the standard medium (1 mg/mL), the TBARS assay was
used38. The ﬁnal concentrations of reactants are indicated in par-
entheses. The peroxidation reaction was initiated by addition of FeCl2
(20 μmol/L)/ascorbate (100 μmol/L) or AAPH (10 mmol/L), and
inhibited by addition of the MitoHCAs (6 μmol/L). After incubation
for 30 min, a TCA-TBA-HCl stock solution (15% w/v TCA; 0.375%
w/v TBA; 0.25 mol/L HCl), together with 0.02% (w/v) butylated
hydroxytoluene, was added. The solution was heated in a hot-water
bath for 15 min. After cooling to room temperature, the precipitate
was removed by centrifugation and the absorbance of the supernatant
was determined at 532 nm38. The amount of malondialdehyde (MDA)
was calculated using ε532¼1.5 105 mol/(L  cm).
4.3.3. Measurement of mitochondrial H2O2 and O
 ∙
2 production
H2O2 and O
 ∙
2 production were assessed using the ﬂuorescents
probes DCFDA and DHE, respectively39. DCFDA probe (8 μmol/L)
or DHE probe (5 μmol/L) was added to 1 mg/mL of energized
mitochondria suspension in the standard medium. MitoHCAs were
added and the suspension was incubated for either 15 or 30 min in
the dark at 25 1C. DCFDA was detected with excitation and
emission wavelengths of 485 nm and 521 nm, respectively. DHE
was detected with excitation and emission wavelengths of 470 nm
and 585 nm, respectively.
4.3.4. Measurement of mitochondrial SOD, GPx and CAT
activities
Mitochondrial SOD, GSH-Px and CAT activities were determined
according to the instructions from the commercial kits (Nanjing
Jiancheng Bioengineering Institute). Brieﬂy, after incubation with
the tested compounds for 15 or 30 min at 30 1C, the mitochondria
were sonicated at 400 A every 5 s for 5 cycles. Enzyme activities
were determined as described in the instructions. Controlled
experiments determined that the tested compounds did not inter-
fere with the assays.4.3.5. Cell culture
HepG2, L02, and WI38 cells were obtained from the Shanghai
Institute of Biochemistry and Cell Biology, Chinese Academy of
Science. HepG2 cells were cultured in 1640 media supplemented
with 10% fetal bovine serum and 1% penicillin-streptomycin at
37 1C under a 5% CO2 atmosphere. L02 and WI38 cells were
cultured in DMEM media supplemented with 10% fetal bovine
serum and 1% penicillin–streptomycin at 37 1C under a 5% CO2
atmosphere.
4.3.6. SRB assay
Antiproliferative activity was determined using the SRB assay,
which estimates cell number indirectly by measuring total protein
concentration. 5 104 adherent cells/well were incubated in 96-
well microtiter plates for 24 h. Following the addition of the test
compounds the plates were incubated for an additional 24 h and
48 h, after which the plates were treated as described by the
standard SRB method32. The absorbance was read at 540 nm on a
microplate reader. IC50 values were determined from a log plot of
percent of control versus concentration.
4.3.7. Flow cytometric analysis
HepG2 cells (5 105/well) were seeded in six-well plates and
incubated for 24 h to allow for exponential growth and then treated
with the test compounds for another 24 h. The cells were collected
and washed with phosphate-buffered saline (PBS). Apoptotic cells
were labeled with annexinV–FITC/PI according to the manufac-
turer's instructions (Beyotime Institute of Biotechnology, Jiangsu,
China). Cells were analyzed on a FACSCanto ﬂow cytometer
(Becton Dickinson, LSRFortessa, USA).
4.3.8. Measurement of mitochondrial morphology
HepG2 cells were grown on coverslips at 5 105 cells/wells inside
6-well plates overnight and then treated with the test compounds
for 4 h. After treatment, the media was removed from the dish and
the cells were washed 3 times with pre-warmed PBS. The cells
were stained and incubated at 37 1C for 30 min with 50 nmol/L
MitoTracker Green FM. After staining, cells were washed twice
with PBS. The coverslips were inverted onto glass slides with
10 μL of an antifade mounting medium (Beyotime). Confocal
images were obtained using a confocal laser-scanning microscope
(Zessi, LSM 510 META, Germany).
4.3.9. Measurement of mitochondrial membrane potential and
swelling
MMP was measured using the ﬂuorescence dye Rhodamine 12340.
Brieﬂy, 0.15 μmol/L Rhodamine 123 was added to energized
isolated hepatic mitochondria (1 mg/mL) in the standard medium
(excitation and emission wavelengths of 503 and 523 nm, respec-
tively). After a short incubation for signal stabilization, the
compounds were added as indicated in the legend to Fig. 6.
Finally, the respiratory uncoupler CCCP (1 μmol/L) was used to
fully depolarize MMP. Mitochondrial swelling was determined by
measuring the apparent A540 change of the mitochondrial suspen-
sion41. Energized isolated hepatic mitochondria (1 mg/mL) were
incubated in the standard medium. Further compounds were added
as indicated in the Fig. 5 legend.
4.3.10. Measurement of cyt c release
Immunoblotting was performed as follows: the mitochondria
(2 mg protein/mL) were incubated for 15 min at 25 1C in standard
Jiyu Li et al.114medium with the test compounds. The reaction mixtures were then
centrifuged at 12,000 g for 10 min at 4 1C to obtain mitochon-
drial pellets. The supernatant fractions were centrifuged further at
100,000 g for 15 min at 4 1C to eliminate mitochondrial
membrane fragments, and then were concentrated by ultraﬁltration
with a Centricon YM-3. Twenty microliter aliquots of the
concentrated supernatants were subjected to electrophoresis on a
12% SDS-PAGE gel. The gel was transferred to a polyvinylidine
ﬂuoride membrane for immunoblotting analysis. VDAC1 was
used as a loading control. The protein bands were visualized using
the Gel Imaging System (ChemDoc-It610, UVP, USA). The
dithionite-reduction assay was performed as follows: (1) energized
hepatic mitochondria (2 mg/mL) were treated with MitoHCAs at
the desired concentrations for 15 min; (2) mitochondria were
centrifuged at 12,000 g for 10 min; (3) dithionite (1.2 mg) was
added to 4.0 mL of the supernatant; (4) the amount of cyt c was
determined at 550 nm42. The extinction coefﬁcient of E1%1 cm is 23.
4.3.11. Statistical analysis
The data are expressed as the mean7SEM. Statistical differences
between two groups were assessed by the Student's t-test. And
Po0.05 was used as the criterion for statistical signiﬁcance.
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